Do analysts prefer STX or TAO?

Shield Therapeutics currently has a consensus price target of GBX 15, suggesting a potential upside of 279.75%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Shield Therapeutics is more favorable than TAO Alpha. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shield Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 TAO Alpha 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, STX or TAO?

TAO Alpha has lower revenue, but higher earnings than Shield Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Shield Therapeutics £49.70M 0.85 -£36.28M -£2.00 N/A TAO Alpha N/A N/A -£1.57M N/A N/A

Do analysts recommend APC or STX?

Shield Therapeutics has a consensus price target of GBX 15, indicating a potential upside of 279.75%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Shield Therapeutics is more favorable than Apc Technology Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apc Technology Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Shield Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts recommend DGI or STX?

Shield Therapeutics has a consensus target price of GBX 15, indicating a potential upside of 279.75%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Shield Therapeutics is more favorable than DG Innovate. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DG Innovate 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Shield Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has better valuation & earnings, DGI or STX?

DG Innovate has higher earnings, but lower revenue than Shield Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DG Innovate £24.50K 0.00 -£4.91M N/A N/A Shield Therapeutics £49.70M 0.85 -£36.28M -£2.00 N/A

Shield Therapeutics (STX) Competitors

GBX 3.95 -0.45 (-10.23%)

As of 07/31/2026 12:33 PM Eastern

Compare

STX vs. ELX, TAO, APC, DGI, and IDEA

Should you buy Shield Therapeutics stock or one of its competitors? MarketBeat compares Shield Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Shield Therapeutics include El Oro (ELX), TAO Alpha (TAO), Apc Technology Group (APC), DG Innovate (DGI), and Ideagen (IDEA).

How does Shield Therapeutics compare to El Oro?

Shield Therapeutics (LON:STX) and El Oro (LON:ELX) are related small-cap companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Shield Therapeutics presently has a consensus target price of GBX 15, indicating a potential upside of 279.75%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Shield Therapeutics is more favorable than El Oro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
El Oro	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Shield Therapeutics had 4 more articles in the media than El Oro. MarketBeat recorded 4 mentions for Shield Therapeutics and 0 mentions for El Oro. Shield Therapeutics' average media sentiment score of 0.66 beat El Oro's score of 0.49 indicating that Shield Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Shield Therapeutics	Positive
El Oro	Neutral

6.7% of Shield Therapeutics shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

El Oro has lower revenue, but higher earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than El Oro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shield Therapeutics	£49.70M	0.85	-£36.28M	-£2.00	N/A
El Oro	-£7.25M	0.00	N/A	-£2.50	N/A

El Oro has a net margin of 0.00% compared to Shield Therapeutics' net margin of -35.72%. Shield Therapeutics' return on equity of 121.87% beat El Oro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shield Therapeutics	-35.72%	121.87%	-47.85%
El Oro	N/A	N/A	N/A

Summary

Shield Therapeutics beats El Oro on 11 of the 13 factors compared between the two stocks.

How does Shield Therapeutics compare to TAO Alpha?

Shield Therapeutics (LON:STX) and TAO Alpha (LON:TAO) are related small-cap companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

6.7% of Shield Therapeutics shares are held by institutional investors. Comparatively, 0.7% of TAO Alpha shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by insiders. Comparatively, 98.3% of TAO Alpha shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

TAO Alpha has lower revenue, but higher earnings than Shield Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shield Therapeutics	£49.70M	0.85	-£36.28M	-£2.00	N/A
TAO Alpha	N/A	N/A	-£1.57M	N/A	N/A

In the previous week, Shield Therapeutics had 4 more articles in the media than TAO Alpha. MarketBeat recorded 4 mentions for Shield Therapeutics and 0 mentions for TAO Alpha. Shield Therapeutics' average media sentiment score of 0.66 beat TAO Alpha's score of 0.00 indicating that Shield Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Shield Therapeutics	Positive
TAO Alpha	Neutral

Shield Therapeutics currently has a consensus price target of GBX 15, suggesting a potential upside of 279.75%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Shield Therapeutics is more favorable than TAO Alpha.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
TAO Alpha	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

TAO Alpha has a net margin of 0.00% compared to Shield Therapeutics' net margin of -35.72%. Shield Therapeutics' return on equity of 121.87% beat TAO Alpha's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shield Therapeutics	-35.72%	121.87%	-47.85%
TAO Alpha	N/A	-128.73%	-64.09%

Summary

Shield Therapeutics beats TAO Alpha on 10 of the 13 factors compared between the two stocks.

How does Shield Therapeutics compare to Apc Technology Group?

Apc Technology Group (LON:APC) and Shield Therapeutics (LON:STX) are related small-cap companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

In the previous week, Shield Therapeutics had 4 more articles in the media than Apc Technology Group. MarketBeat recorded 4 mentions for Shield Therapeutics and 0 mentions for Apc Technology Group. Shield Therapeutics' average media sentiment score of 0.66 beat Apc Technology Group's score of 0.00 indicating that Shield Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Apc Technology Group	Neutral
Shield Therapeutics	Positive

Apc Technology Group has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Apc Technology Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apc Technology Group	£19.20M	0.00	N/A	£0.50	N/A
Shield Therapeutics	£49.70M	0.85	-£36.28M	-£2.00	N/A

Shield Therapeutics has a consensus price target of GBX 15, indicating a potential upside of 279.75%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Shield Therapeutics is more favorable than Apc Technology Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apc Technology Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Apc Technology Group has a net margin of 0.00% compared to Shield Therapeutics' net margin of -35.72%. Shield Therapeutics' return on equity of 121.87% beat Apc Technology Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apc Technology Group	N/A	N/A	N/A
Shield Therapeutics	-35.72%	121.87%	-47.85%

6.7% of Shield Therapeutics shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Shield Therapeutics beats Apc Technology Group on 9 of the 13 factors compared between the two stocks.

How does Shield Therapeutics compare to DG Innovate?

DG Innovate (LON:DGI) and Shield Therapeutics (LON:STX) are related small-cap companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

DG Innovate has a beta of 3.55, meaning that its share price is 255% more volatile than the broader market. Comparatively, Shield Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

DG Innovate has a net margin of 0.00% compared to Shield Therapeutics' net margin of -35.72%. Shield Therapeutics' return on equity of 121.87% beat DG Innovate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DG Innovate	N/A	-129.16%	-50.26%
Shield Therapeutics	-35.72%	121.87%	-47.85%

Shield Therapeutics has a consensus target price of GBX 15, indicating a potential upside of 279.75%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Shield Therapeutics is more favorable than DG Innovate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DG Innovate	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

8.0% of DG Innovate shares are owned by institutional investors. Comparatively, 6.7% of Shield Therapeutics shares are owned by institutional investors. 45.7% of DG Innovate shares are owned by insiders. Comparatively, 3.0% of Shield Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Shield Therapeutics had 4 more articles in the media than DG Innovate. MarketBeat recorded 4 mentions for Shield Therapeutics and 0 mentions for DG Innovate. DG Innovate's average media sentiment score of 1.30 beat Shield Therapeutics' score of 0.66 indicating that DG Innovate is being referred to more favorably in the media.

Company	Overall Sentiment
DG Innovate	Positive
Shield Therapeutics	Positive

DG Innovate has higher earnings, but lower revenue than Shield Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DG Innovate	£24.50K	0.00	-£4.91M	N/A	N/A
Shield Therapeutics	£49.70M	0.85	-£36.28M	-£2.00	N/A

Summary

DG Innovate and Shield Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Shield Therapeutics compare to Ideagen?

Shield Therapeutics (LON:STX) and Ideagen (LON:IDEA) are related small-cap companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Ideagen has a net margin of 0.00% compared to Shield Therapeutics' net margin of -35.72%. Shield Therapeutics' return on equity of 121.87% beat Ideagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shield Therapeutics	-35.72%	121.87%	-47.85%
Ideagen	N/A	N/A	N/A

Ideagen has higher revenue and earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Ideagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shield Therapeutics	£49.70M	0.85	-£36.28M	-£2.00	N/A
Ideagen	£75.28M	0.00	N/A	£0.02	N/A

6.7% of Shield Therapeutics shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Shield Therapeutics had 4 more articles in the media than Ideagen. MarketBeat recorded 4 mentions for Shield Therapeutics and 0 mentions for Ideagen. Shield Therapeutics' average media sentiment score of 0.66 beat Ideagen's score of 0.00 indicating that Shield Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Shield Therapeutics	Positive
Ideagen	Neutral

Shield Therapeutics presently has a consensus price target of GBX 15, indicating a potential upside of 279.75%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Shield Therapeutics is more favorable than Ideagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ideagen	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Shield Therapeutics beats Ideagen on 8 of the 13 factors compared between the two stocks.

Get Shield Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STX vs. The Competition

Export

Metric	Shield Therapeutics	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£47.06M	£12.89B	£7.23B	£2.78B
Dividend Yield	N/A	2.72%	2.59%	6.15%
P/E Ratio	-1.98	799.04	282.64	368.29
Price / Sales	0.85	938.33	641.27	83,501.19
Price / Cash	6.36	76.57	71.02	27.89
Price / Book	72.18	10.92	11.09	7.04
Net Income	-£36.28M	£2.82B	£3.50B	£5.89B
7 Day Performance	-34.28%	-0.06%	-0.24%	6.44%
1 Month Performance	-37.30%	-3.17%	-2.97%	0.09%
1 Year Performance	-12.22%	155.28%	61.94%	63.74%

Shield Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STX Shield Therapeutics	1.5795 of 5 stars	GBX 3.95 -10.2%	GBX 15 +279.7%	-12.8%	£47.06M	£49.70M	N/A	40,000	News Coverage High Trading Volume
ELX El Oro	N/A	N/A	N/A	N/A	£41.06M	-£7.25M	N/A	1,122
TAO TAO Alpha	N/A	GBX 7.10 +31.5%	N/A	+0.0%	£26.89M	N/A	N/A	3	Gap Up High Trading Volume
APC Apc Technology Group	N/A	N/A	N/A	N/A	£18.03M	£19.20M	19.75	164,000
DGI DG Innovate	N/A	N/A	N/A	N/A	£1.90M	£24.50K	N/A	790	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:STX) was last updated on 8/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shield Therapeutics (STX) Competitors

STX vs. ELX, TAO, APC, DGI, and IDEA

How does Shield Therapeutics compare to El Oro?

Summary

How does Shield Therapeutics compare to TAO Alpha?

Summary

How does Shield Therapeutics compare to Apc Technology Group?

Summary

How does Shield Therapeutics compare to DG Innovate?

Summary

How does Shield Therapeutics compare to Ideagen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STX vs. The Competition

Shield Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shield Therapeutics (STX) Competitors

STX vs. ELX, TAO, APC, DGI, and IDEA

How does Shield Therapeutics compare to El Oro?

Do analysts prefer STX or ELX?

Does the media favor STX or ELX?

Do institutionals and insiders believe in STX or ELX?

Which has better earnings and valuation, STX or ELX?

Is STX or ELX more profitable?

Summary

How does Shield Therapeutics compare to TAO Alpha?

Do institutionals & insiders have more ownership in STX or TAO?

Which has higher valuation & earnings, STX or TAO?

Does the media refer more to STX or TAO?

Do analysts prefer STX or TAO?

Is STX or TAO more profitable?

Summary

How does Shield Therapeutics compare to Apc Technology Group?

Does the media prefer APC or STX?

Which has better earnings & valuation, APC or STX?

Do analysts recommend APC or STX?

Is APC or STX more profitable?

Do institutionals and insiders believe in APC or STX?

Summary

How does Shield Therapeutics compare to DG Innovate?

Which has more risk & volatility, DGI or STX?

Is DGI or STX more profitable?

Do analysts recommend DGI or STX?

Do insiders and institutionals believe in DGI or STX?

Does the media favor DGI or STX?

Which has better valuation & earnings, DGI or STX?

Summary

How does Shield Therapeutics compare to Ideagen?

Is STX or IDEA more profitable?

Which has stronger earnings and valuation, STX or IDEA?

Do institutionals & insiders believe in STX or IDEA?

Does the media prefer STX or IDEA?

Do analysts recommend STX or IDEA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STX vs. The Competition

Shield Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools